1 – 45 of 45
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Antiviral tablettbehandling av covid-19 – ett värdefullt tillskott
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
COVID-19 hospitalization outcomes in adults by HIV status; a nation-wide register-based study
(
- Contribution to journal › Article
-
Mark
The molecular epidemiology of HIV-1 in Sweden 1996 to 2022, and the influence of migration from Ukraine
2023) In Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 28(48).(
- Contribution to journal › Article
-
Mark
Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure - two nationwide, population-based cohort studies
(
- Contribution to journal › Article
-
Mark
Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden
(
- Contribution to journal › Article
-
Mark
Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronaviruses
(
- Contribution to journal › Article
-
Mark
Longitudinal single-cell analysis of SARS-CoV-2-reactive B cells uncovers persistence of early-formed, antigen-specific clones
(
- Contribution to journal › Article
- 2022
-
Mark
Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy : A Swedish observational study
(
- Contribution to journal › Article
-
Mark
Associations between HIV viremia during antiretroviral therapy and cardiovascular disease
(
- Contribution to journal › Article
-
Mark
Confirmed reinfection with SARS-CoV-2 during a pregnancy : A case report
(
- Contribution to journal › Article
-
Mark
Severe COVID-19 in people 55 and older during the first year of the pandemic in Sweden
(
- Contribution to journal › Article
-
Mark
COVID-19 in people aged 18–64 in Sweden in the first year of the pandemic : Key factors for severe disease and death
(
- Contribution to journal › Article
-
Mark
Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls
(
- Contribution to journal › Article
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article
- 2021
-
Mark
Associations between Plasma HIV RNA Levels and Incidence of Invasive Cancer in People with HIV after Initiation of Combination Antiretroviral Therapy
2021) In Open Forum Infectious Diseases(
- Contribution to journal › Article
-
Mark
Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4
+ T-Cell Responses.
(
- Contribution to journal › Article
-
Mark
Infection of brain pericytes underlying neuropathology of covid‐19 patients
(
- Contribution to journal › Article
-
Mark
Association of cardiometabolic risk factors with hospitalisation or death due to COVID-19 : population-based cohort study in Sweden (SCAPIS)
(
- Contribution to journal › Article
-
Mark
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) : a structured summary of a study protocol for a randomised controlled trial
(
- Contribution to journal › Letter
- 2020
-
Mark
Low-Level Viremia during ART and the Risk of Death, AIDS, and Serious Non-AIDS-events
(
- Contribution to conference › Abstract
-
Mark
All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study
2020) In Clinical Infectious Diseases(
- Contribution to journal › Article
-
Mark
Antiretroviral treatment for HIV infection : Swedish recommendations 2019
(
- Contribution to journal › Scientific review
-
Mark
Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders
(
- Contribution to journal › Article
- 2018
-
Mark
Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations
(
- Contribution to journal › Article
-
Mark
Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden
(
- Contribution to journal › Article
- 2017
-
Mark
Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
(
- Contribution to journal › Article
-
Mark
Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients
(
- Contribution to journal › Article
-
Mark
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
(
- Contribution to journal › Article
- 2016
-
Mark
Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
(
- Contribution to journal › Article
-
Mark
Reduced baseline sensitivity to Maraviroc inhibition among R5 HIV-1 isolates from individuals with severe immunodeficiency.
(
- Contribution to journal › Letter
- 2015
-
Mark
Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.
(
- Contribution to journal › Article
- 2014
-
Mark
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013
(
- Contribution to journal › Scientific review
-
Mark
Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial
(
- Contribution to journal › Article
- 2012
-
Mark
Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load
(
- Contribution to journal › Article
-
Mark
Low Prevalence of Transmitted Drug Resistance in Patients Newly Diagnosed with HIV-1 Infection in Sweden 2003-2010
(
- Contribution to journal › Article
- 2011
-
Mark
Bilirubin-A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy
(
- Contribution to journal › Article
-
Mark
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naive HIV-1 infected patients
(
- Contribution to journal › Article
-
Mark
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010
(
- Contribution to journal › Scientific review
- 2010
-
Mark
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na
- Contribution to journal › Article
-
Mark
Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naive HIV-1-Infected Patients
(
- Contribution to journal › Article
- 2009
-
Mark
Treatment of HIV infection: Swedish recommendations 2009
(
- Contribution to journal › Scientific review
-
Mark
Mode of Coreceptor Use by R5 HIV Type 1 Correlates with Disease Stage: A Study of Paired Plasma and Cerebrospinal Fluid Isolates.
(
- Contribution to journal › Article
- 2008
-
Mark
Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.
(
- Contribution to journal › Article
-
Mark
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2007
(
- Contribution to journal › Scientific review